<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah J Wexler, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sulfonylureas and meglitinides directly stimulate release of insulin from pancreatic beta cells and thereby lower blood glucose concentrations. Because they work by stimulating insulin secretion, they are useful only in patients with some beta cell function. Adverse effects may include weight gain and hypoglycemia. The pharmacology, efficacy, indications, and side effects of these drugs will be discussed here. A general discussion of initial and subsequent treatment of type 2 diabetes is reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">(Related Pathway(s):  <a class="utd-content-120430" href="/pathway/120430?topicRef=1786&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a>.)</span></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-129531">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1786&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p></p><p class="headingAnchor" id="H2"><span class="h1">SULFONYLUREAS</span></p><p class="headingAnchor" id="H4067348528"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>The sulfonylurea receptor is a component of the adenosine triphosphate (ATP)-sensitive potassium channel (K-ATP channel) in the pancreatic beta cells [<a href="#rid1">1</a>]. The K-ATP channel regulates the release of insulin from pancreatic beta cells. Sulfonylurea binding leads to inhibition of these channels, which alters the resting potential of the cell, leading to calcium influx and stimulation of insulin secretion. The net effect is increased responsiveness of beta cells to both glucose and non-glucose secretagogues (such as amino acids), resulting in more insulin being released at all blood glucose concentrations. Sulfonylureas may also have extrapancreatic effects, one of which is to increase tissue sensitivity to insulin, but the clinical importance of these effects is minimal [<a href="#rid2">2</a>].</p><p>The K-ATP channel is a functional complex of the sulfonylurea 1 receptor (SUR1) and an inward rectifier potassium channel subunit Kir6.2. Mutations in either the <em>SUR1</em> gene or the Kir6.2 gene lead to the loss of K-ATP activity; as a result, the cell is persistently depolarized, resulting in calcium influx, high cytosolic calcium concentrations, and the release of insulin, producing a syndrome called persistent hyperinsulinemic hypoglycemia of infancy. (See  <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">"Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism"</a>.)</p><p>Mutations in the Kir6.2 and, to a lesser extent, the <em>SUR1</em> gene, have also been identified that activate the K-ATP channel [<a href="#rid3">3,4</a>]. Activating mutations increase the number of open K-ATP channels at the plasma membrane, hyperpolarizing the beta cells and preventing the release of insulin. These mutations have been found in patients with permanent neonatal diabetes mellitus; insulin secretion in these patients can be restored with <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia"</a>.)</p><p class="headingAnchor" id="H2382666243"><span class="h2">Clinical use of sulfonylureas</span></p><p class="headingAnchor" id="H1888065414"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Initial treatment of patients with type 2 diabetes mellitus includes education, with emphasis on lifestyle changes including diet, exercise, and weight reduction when appropriate. Initial therapy with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, rather than a sulfonylurea, is indicated for most patients. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'</a>.)</p><p>Sulfonylureas can be used as initial therapy in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications to </strong><strong>metformin</strong> – A short-acting sulfonylurea (eg, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>) is an option for patients who have contraindications to or intolerance of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, particularly if cost is a concern. In a meta-analysis of 31 trials, sulfonylurea monotherapy (nine trials) lowered A1C by 1.5 percentage points more than placebo [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hyperglycemia</strong> (fasting plasma glucose &gt;250 mg/dL [13.9 mmol/L], random glucose consistently &gt;300 mg/dL [16.7 mmol/L], glycated hemoglobin [A1C] &gt;9 percent [74.9 mmol/mol]) but without ketonuria or unintentional weight loss – In this setting, insulin or a glucagon-like peptide 1 (GLP-1) receptor agonist are the preferred initial therapies. However, for patients who refuse or cannot afford injectable agents, initial therapy with high-dose sulfonylurea is an alternative option and can rapidly reduce hyperglycemia in patients with severe hyperglycemia [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Insulin should be used in patients (regardless of age) who are underweight, are losing weight, or are ketotic despite adequate caloric intake. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Symptomatic (catabolic) or severe hyperglycemia'</a> and  <a class="medical medical_review" href="/z/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Indications for insulin'</a>.)</p><p></p><p class="bulletIndent1">Some of these latter patients may actually have type 1 diabetes, which can be confirmed by the presence of autoantibodies (eg, glutamic acid decarboxylase [GAD]-65 and islet antigen [IA]-2). (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Distinguishing type 1 from type 2 diabetes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maturity onset diabetes of the young (MODY)</strong> – MODY is a clinically heterogeneous disorder characterized by non-insulin-dependent diabetes diagnosed at a young age (&lt;25 years) with autosomal dominant transmission and lack of autoantibodies. Several different genetic abnormalities have been identified, each leading to a different type of disease. The subtypes of MODY are defined by specific descriptions of the known genetic defects  (<a class="graphic graphic_table graphicRef83071" href="/z/d/graphic/83071.html" rel="external">table 1</a>). Patients with mutations in the <em>HNF1A</em> and <em>HNF4A</em> gene (formerly known as MODY subtypes 3 and 1, respectively), two of the three most common MODY subtypes, can be successfully treated with sulfonylurea monotherapy. Such patients can be safely transitioned from insulin to sulfonylureas with as good or better glycemic management [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Monogenic diabetes (formerly called maturity onset diabetes of the young)'</a>.)</p><p></p><p class="headingAnchor" id="H3896839816"><span class="h3">Combination therapy</span><span class="headingEndMark"> — </span>Sulfonylureas are more commonly used in combination with other oral hypoglycemic drugs in patients who fail initial therapy with lifestyle intervention and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. Sulfonylureas generally are not used in combination with insulin. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>.)</p><p>Sulfonylureas usually lower A1C by 1 to 2 percent [<a href="#rid6">6,9</a>]. In a meta-analysis of 31 trials, the addition of sulfonylureas to other oral diabetes treatment (<a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or thiazolidinediones, four trials) lowered A1C by 1.62 percentage points more than placebo [<a href="#rid6">6</a>].</p><p>In a meta-analysis of 179 trials and 25 observational studies evaluating the effects of oral or injectable diabetes medications in combination with other oral agents or insulin on intermediate outcomes (A1C, body weight, lipid profiles), most combinations (including sulfonylurea combinations) similarly reduced A1C levels [<a href="#rid10">10</a>]. In the GRADE comparative effectiveness trial in 5047 patients with type 2 diabetes with a mean five-year follow-up, participants who were randomly assigned to <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> as add-on treatment to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> monotherapy had a cumulative incidence of A1C ≥7 percent (72 percent) that was only modestly higher than the incidence with <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> (68 percent) or glargine (67 percent) and lower than that with <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> (77 percent) [<a href="#rid11">11</a>]. </p><p>The choice of a sulfonylurea over other oral or injectable agents balances glucose-lowering efficacy, universal local availability, and low cost with risk of hypoglycemia and weight gain. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H2626341772"><span class="h3">Precautions</span></p><p class="headingAnchor" id="H2984339487"><span class="h4">Sulfonamide allergies</span><span class="headingEndMark"> — </span>Concern regarding potential crossreactivity of sulfonamide antimicrobials (eg, sulfamethoxazole, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>) and sulfonylureas, with an increased risk for allergic reactions to sulfonylureas in patients with a history of "sulfa allergies," appears to be unfounded and is no longer listed as a contraindication in the package insert for immediate-release <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>. Although hypersensitivity to sulfonamides is still listed as a warning for <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> and <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> and a contraindication for <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> and glipizide extended release, sulfonylureas are commonly used in patients with professed allergies to sulfonamide antimicrobials without any problems. (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Between sulfonamide antimicrobials and nonantimicrobials'</a>.)</p><p class="headingAnchor" id="H3619003472"><span class="h4">Use in chronic kidney disease</span><span class="headingEndMark"> — </span>Sulfonylurea metabolites are renally excreted. Some of these metabolites (such as those of <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> [glibenclamide]) are active or have weak hypoglycemic activity. Therefore, the risk of hypoglycemia is higher in patients with chronic kidney disease. Shorter-acting sulfonylurea medications with mostly inactive metabolites (eg, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a>) are preferred. (See <a class="local">'Choice of sulfonylurea'</a> below and  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Patients not on dialysis'</a>.)</p><p class="headingAnchor" id="H641864162"><span class="h3">Choice of sulfonylurea</span><span class="headingEndMark"> — </span>When a decision has been made to treat with a sulfonylurea, we suggest a shorter-duration sulfonylurea (eg, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> [not available in the United States]) or one with relatively lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a>). Observational and randomized studies have supported lower frequency of hypoglycemia with gliclazide or glipizide than with longer-acting sulfonylureas [<a href="#rid12">12-14</a>]. (See <a class="local">'Hypoglycemia'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with nondialysis chronic kidney disease, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> or <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> are preferred formulations since glipizide is shorter acting than <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> and both are metabolized by the liver and primarily excreted in the urine as inactive metabolites. (See  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Patients not on dialysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with established cardiovascular disease (CVD), we prefer an agent that has demonstrated cardiovascular benefit (eg, GLP-1 receptor agonist or sodium-glucose co-transporter 2 [SGLT2] inhibitor). (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p></p><p class="bulletIndent1">If these agents are unavailable or not tolerated, and a sulfonylurea is required for additional glucose-lowering, we prefer to use <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> based on the results of the CAROLINA (Cardiovascular Outcomes Study of <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">Linagliptin</a> versus Glimepiride in Patients with Type 2 Diabetes) randomized clinical trial, which compared glimepiride with linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in 6033 patients over a median 6.3 years and found no difference in cardiovascular outcome [<a href="#rid15">15</a>]. This trial, along with a similarly designed trial comparing linagliptin with placebo that did not show an increased risk of major adverse cardiovascular events, provides reassurance of the cardiovascular safety of glimepiride [<a href="#rid16">16,17</a>]. (See <a class="local">'Cardiovascular effects'</a> below.)</p><p></p><p>There is a paucity of trials comparing the relative effectiveness and safety of the individual sulfonylureas. There is a relatively high incidence of hypoglycemia and other adverse effects in patients taking <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> (glibenclamide), due in part to the formation of active metabolites [<a href="#rid18">18</a>] (see <a class="local">'Hypoglycemia'</a> below). First-generation sulfonylureas (eg, chlorpropamide, <a class="drug drug_general" data-topicid="10003" href="/z/d/drug information/10003.html" rel="external">tolbutamide</a>) are not commonly available or used. They differed from currently available sulfonylureas owing to their long duration of action and increased risk for hypoglycemia (chlorpropamide), other adverse effects such as hyponatremia and disulfiram-like effects (chlorpropamide), and because of old studies that suggested increased cardiovascular risk (tolbutamide)  (<a class="graphic graphic_table graphicRef56701" href="/z/d/graphic/56701.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3760391596"><span class="h3">Dosing and monitoring</span><span class="headingEndMark"> — </span>The recommended dose range for most of the available drugs is shown in the table  (<a class="graphic graphic_table graphicRef56701" href="/z/d/graphic/56701.html" rel="external">table 2</a>). The art of sulfonylurea dosing departs somewhat from the "science" or recommended dose range on the package insert. For patients who are lean, have chronic kidney disease, or are frail or older, who are taking a sulfonylurea rather than a medication that does not cause hypoglycemia, we start at the lower end of the dose range and advance slowly. For younger, more insulin-resistant patients with severe hyperglycemia, we start with higher doses. For patients with variable diet and activity, we recommend variable dosing appropriate to meal size and scheduled activity. All patients treated with sulfonylureas should receive education regarding when to hold the medication (for increased physical activity or when not eating) and recognition and management of hypoglycemia. (See <a class="local">'Hypoglycemia'</a> below.)</p><p>A typical low-dose initial sulfonylurea regimen consists of:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">Glipizide</a>, 2.5 mg of glipizide taken 30 minutes before breakfast.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">Glimepiride</a>, 1 to 2 mg with breakfast. For patients at increased risk for hypoglycemia (older, chronic kidney disease), the initial dose should be 1 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">Gliclazide</a>, 40 to 80 mg daily (40 mg for older patients and those with chronic kidney disease) or gliclazide MR 30 mg daily (one tablet of gliclazide 80 mg is comparable with gliclazide MR 30 mg daily, a longer-acting formulation).</p><p></p><p>The glucose-lowering effects of sulfonylureas with dose changes are seen quickly, and rapid titration can be performed if adequate glycemic management is not attained based on blood glucose monitoring. We typically recommend spot checking before meals and bedtime over the course of the week, to cover all time points; however, routine testing four times every day is usually not required. Routine blood glucose monitoring may be stopped when the safety and stability of the regimen is established. (See  <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'Non-insulin treated'</a>.)</p><p>The dose can be adjusted every one to four weeks based on response and risk of hypoglycemia.</p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, 5 mg and then 10 mg, given before breakfast or before breakfast and the evening meal may be sufficient. The maximum dose of glipizide is noted to be up to 40 mg/day in the labeling. However, doses higher than 20 mg/day rarely improve glycemic management, and higher doses should generally be avoided [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a>, the dose can be increased in 1 or 2 mg increments based upon glycemic response (usual daily dose 2 to 4 mg daily, but up to 4 mg twice daily or 8 mg daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a>, the dose can be increased in 40 to 80 mg increments (usually 40 mg). Doses of 160 mg or greater should be taken in divided doses with breakfast and dinner (maximum daily dose 320 mg)  (<a class="graphic graphic_table graphicRef56701" href="/z/d/graphic/56701.html" rel="external">table 2</a>). For gliclazide MR, the dose is increased in 30 mg increments (maximum daily dose 120 mg).</p><p></p><p>A typical high-dose sulfonylurea regimen (for severe or symptomatic hyperglycemia) is <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> 4 or 8 mg once daily. An alternative option is immediate-release <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> 10 mg twice daily (or, where available, <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> immediate release 80 mg daily). (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Symptomatic (catabolic) or severe hyperglycemia'</a>.)</p><p>For patients taking a sulfonylurea, we measure A1C every three to six months. For patients with impaired kidney function, creatinine should be measured every 6 to 12 months.</p><p class="headingAnchor" id="H3692852977"><span class="h2">Cardiovascular effects</span><span class="headingEndMark"> — </span>Overall, there does not appear to be an increased risk of cardiovascular events with second-generation sulfonylureas [<a href="#rid15">15,20-23</a>]. Any increase in relative risk for CVD events compared with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is thought to be secondary to the benefits of metformin, which appears to reduce the risk for myocardial infarction [<a href="#rid24">24</a>]. Our general recommendation is to have most patients with type 2 diabetes treated with metformin as a first medication, with sulfonylureas as one of the medication classes to add if needed. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall cardiovascular risk</strong> – In a meta-analysis of 115 trials (of at least six months duration) comparing sulfonylureas with an active comparator in patients with type 2 diabetes, there was no difference in the incidence of major cardiovascular events, although overall mortality (but not cardiovascular mortality) was increased (odds ratio [OR] 1.22, 95% CI 1.01-1.49) [<a href="#rid20">20</a>]. In a subsequent meta-analysis of 47 trials (of at least one year duration) comparing second-generation sulfonylureas (glibenclamide, <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a>, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, and <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a>) with diet, placebo, or an active comparator, sulfonylureas were not associated with an increased risk of overall mortality, cardiovascular mortality, myocardial infarction, or stroke [<a href="#rid21">21</a>]. The trials in these meta-analyses were not specifically designed to evaluate cardiovascular safety.</p><p></p><p class="bulletIndent1">In a specifically designed cardiovascular outcomes trial (CAROLINA) comparing <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a> with <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> in 6042 patients with type 2 diabetes and elevated cardiovascular risk (median follow-up of 6.3 years), the occurrence of the composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was similar in the two groups (11.8 versus 12 percent with glimepiride, hazard ratio [HR] 0.98, 95% CI 0.84-1.14) [<a href="#rid15">15</a>]. Hospitalization for heart failure did not differ between the two groups. Rates of severe hypoglycemia (0.07 versus 0.45 per 100 patient-years) and hospitalization for hypoglycemia (0.01 versus 0.18 per 100 patient-years) were low in both groups, albeit higher in the sulfonylurea group. This trial, along with a similarly designed trial (CARMELINA) comparing linagliptin with placebo that did not show an increased risk of major adverse cardiovascular events, provides reassurance of the cardiovascular safety of glimepiride [<a href="#rid16">16,17</a>].</p><p></p><p class="bulletIndent1">Similarly, in the GRADE trial in 5047 participants with type 2 diabetes and low baseline cardiovascular risk, the rates of prespecified cardiovascular secondary outcomes including major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular mortality were similar with <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> relative to <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> and glargine when added to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> monotherapy [<a href="#rid22">22</a>]. The GRADE trial is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Without established cardiovascular or kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In comparison with </strong><strong>metformin</strong> – A randomized trial and retrospective studies suggest higher rates of cardiac events with sulfonylureas than <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> [<a href="#rid24">24-29</a>]. The relative increased risk for CVD associated with sulfonylureas appears to be due to protective effects of metformin, rather than an adverse cardiovascular effect of sulfonylureas. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> (median follow-up five years) in 304 Chinese patients with a history of coronary heart disease and type 2 diabetes, there were fewer cardiovascular events (composite of nonfatal myocardial infarction [5 versus 6], stroke [10 versus 15], arterial revascularization [21 versus 25], or death from cardiovascular or any cause [7 versus 14]) in the metformin group (total events 43 versus 60; HR 0.54, 95% CI 0.3-0.9) [<a href="#rid25">25</a>]. After three years, the mean achieved A1C level was similar (7 and 7.1 percent) in the two groups. However, body weight, waist circumference, and body mass index (BMI) were significantly lower in the metformin group.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective Canadian study using pharmaceutical data for 5795 patients who received initial monotherapy with either a sulfonylurea or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, deaths per 1000 person-years during the follow-up period (mean 4.8 years) were 67.6 for first-generation sulfonylurea medications, 61.4 for <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>, and 39.6 for metformin [<a href="#rid26">26</a>]. The risk of death or an acute ischemic event was greater for individuals exposed to higher, compared with lower, doses of the sulfonylurea, but not metformin [<a href="#rid26">26</a>]. The greatest risk was for patients taking higher, compared with lower, doses of <a class="drug drug_general" data-topicid="10003" href="/z/d/drug information/10003.html" rel="external">tolbutamide</a> or chlorpropamide (HR 2.1, 95% CI 1.0-4.7).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective cohort study comparing cardiovascular outcomes in 253,690 United States veterans who initiated <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or sulfonylurea for diabetes, the risk of a composite cardiovascular outcome (hospitalization for acute myocardial infarction or stroke, or death) was higher in sulfonylurea users (18.2 versus 10.4 per 1000 person-years; HR 1.21, 95% CI 1.13-1.30) with median follow-up of less than one year [<a href="#rid27">27</a>]. There was no difference in CVD risk in patients taking <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> versus <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>. In a subsequent report from the same group, the higher risk of major adverse cardiovascular events noted in sulfonylurea compared with metformin users was also evident in patients with reduced kidney function [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Many other retrospective cohort studies have shown results favoring <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> over sulfonylureas. All of these studies are hindered by various forms of bias, including allocation bias (ie, confounding by indication) in which sulfonylureas are prescribed to patients who cannot take metformin, frequently due to comorbidities (eg, chronic kidney disease), or time lag bias, owing to sulfonylurea usually being started at a later disease stage since metformin is the recommended first medication. Even in studies that use the most sophisticated methods to adjust for allocation bias, there is concern that residual confounding cannot be eliminated, which is why randomized trials provide a much higher quality of evidence. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In patients with acute myocardial infarction</strong> – Some studies suggest that treatment with sulfonylureas may be associated with poorer outcomes in patients who have a myocardial infarction. Increased mortality from CVD in patients with diabetes taking <a class="drug drug_general" data-topicid="10003" href="/z/d/drug information/10003.html" rel="external">tolbutamide</a> was noted over three decades ago in the University Group Diabetes Study [<a href="#rid30">30</a>]. While this study was not supported by results from the United Kingdom Prospective Diabetes Study (UKPDS), which reported no increase in fatality for patients taking sulfonylurea therapy at the time of myocardial infarction [<a href="#rid31">31</a>], other studies have supported the association [<a href="#rid32">32,33</a>]. Most other studies have been observational, have not been able to address allocation bias, and have provided conflicting data.</p><p></p><p class="bulletIndent1">Of note, the newer sulfonylureas (such as <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> and <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>) are highly selective for the pancreatic sulfonylurea receptors over the cardiac K-ATP channel receptors and do not appear to be associated with increased cardiovascular mortality compared with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or other diabetes medications. As noted, however, the only comparative effectiveness clinical trials have been the CAROLINA and GRADE trials, which found no evidence of increased CVD risk with <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> compared with <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a>, <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a>, or <a class="drug drug_general" data-topicid="9023" href="/z/d/drug information/9023.html" rel="external">insulin glargine</a> [<a href="#rid11">11,15,28,34,35</a>].</p><p></p><p class="headingAnchor" id="H1688565770"><span class="h2">Adverse effects</span></p><p class="headingAnchor" id="H2217458310"><span class="h3">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia is a common side effect, although it is generally not severe. In a systematic review of 25 trials comparing sulfonylureas with GLP-1 receptor agonists or DPP-4 inhibitors in patients with type 2 diabetes, severe hypoglycemia (requiring assistance from others) occurred in 0.8 percent of sulfonylurea users, whereas hypoglycemia with glucose ≤56 mg/dL (3.1 mmol/L) or ≤50 mg/dL (2.8 mmol/L) occurred in 10.1 and 5.9 percent, respectively [<a href="#rid36">36</a>]. The overall safety of sulfonylureas when added to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is further supported by the GRADE comparative effectiveness trial in which the cumulative incidence of severe hypoglycemia over five years was low with <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> add-on therapy (2.2 percent), albeit higher than that for <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> (1 percent), glargine (1.3 percent), or <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> (0.7 percent) [<a href="#rid11">11</a>]. </p><p>For initial glucose-lowering therapy, however, sulfonylureas have a higher risk of hypoglycemia than <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. As an example, in an observational study using the UK Clinical Practice Research Datalink, the rate of hypoglycemia requiring hospitalization was 4.1 per 1000 patient-years with sulfonylureas compared with 0.9 with metformin (HR 4.53, 95% CI 2.76-7.45) [<a href="#rid37">37</a>].</p><p>Hypoglycemia may be less common with shorter-acting (<a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a>, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>) than longer-acting (<a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>) sulfonylureas [<a href="#rid36">36,38-40</a>]. In the meta-analysis described above, gliclazide was associated with the lowest risk of hypoglycemia [<a href="#rid36">36</a>]. In a four-year, retrospective study of 14,000 patients 65 years or older with type 2 diabetes treated with different sulfonylurea drugs, episodes of serious hypoglycemia were rare [<a href="#rid41">41,42</a>]. The incidence was highest in those patients taking glyburide; the adjusted relative risk of severe hypoglycemia among glyburide compared with glipizide users was 1.9 (95% CI 1.2-2.9) [<a href="#rid41">41</a>].</p><p>The relative effects of different sulfonylureas with regard to hypoglycemia must be considered with caution, however, as there are very few comparative effectiveness studies that perform head-to-head randomized comparisons. In a short-term study, which compared randomly assigned <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> with <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> MR (available in much of the world, but not in the United States), either as monotherapy or combined with other glucose-lowering drugs, glimepiride was associated with a higher frequency of episodes of hypoglycemia, none of which were classified as severe [<a href="#rid43">43</a>]. A1C was reduced similarly by the two drugs. Of the "third-generation" sulfonylureas (glimepiride and gliclazide MR), gliclazide MR appears to have a lower risk of hypoglycemia [<a href="#rid44">44</a>].</p><p>Patients should be cautioned about those situations in which hypoglycemia is most likely to occur. They are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>After exercise or a missed meal</p><p class="bulletIndent1"><span class="glyph">●</span>When the medication dose is too high</p><p class="bulletIndent1"><span class="glyph">●</span>With the use of longer-acting drugs (<a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> or extended-release formulations)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are undernourished or have food insecurity [<a href="#rid45">45</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of acute or chronic alcohol use</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with impaired kidney or cardiac function or gastrointestinal disease</p><p class="bulletIndent1"><span class="glyph">●</span>With concurrent therapy with salicylates, sulfonamides, fibric acid derivatives (such as <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">gemfibrozil</a>), and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid46">46</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>After being in the hospital [<a href="#rid42">42</a>]</p><p></p><p>The prevention and treatment of sulfonylurea-induced hypoglycemia are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus", section on 'Strategies to manage hypoglycemia'</a> and  <a class="medical medical_review" href="/z/d/html/308.html" rel="external">"Sulfonylurea agent poisoning", section on 'Management'</a>.)</p><p class="headingAnchor" id="H3818504254"><span class="h3">Weight gain</span><span class="headingEndMark"> — </span>Modest weight gain can be a common side effect of sulfonylureas [<a href="#rid47">47</a>]. In one large trial (6033 patients with type 2 diabetes and elevated cardiovascular risk), mean weight gain over 6.3 years was 1.54 kg greater with <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> than with <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a> [<a href="#rid15">15</a>]. Similarly, in the GRADE trial, addition of glimepiride to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> monotherapy resulted in very stable mean body weight over five years [<a href="#rid11">11</a>]. However, the incidence of body weight gain of ≥10 percent was higher with glimepiride (12.1 percent) or glargine (13.1 percent) add-on therapy than with <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> (9.1 percent) or <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> (6.1 percent) [<a href="#rid11">11</a>].</p><p>Weight gain can be mitigated with diabetes education and lifestyle interventions (eg, exercise, diet). However, some individuals seem to be very sensitive to sulfonylurea-associated weight gain. We have a low threshold to stop sulfonylureas in people with substantial weight gain, especially if the weight gain does not stabilize or if it is associated with deterioration, rather than improvement, of glycemic management. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Diabetes education'</a>.)</p><p class="headingAnchor" id="H3992497548"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other, infrequent side effects that can occur with all sulfonylureas include nausea, skin reactions (including pruritus, erythema, rash, urticaria, photosensitivity), and abnormal liver function tests. In a patient with a past allergic reaction to one sulfonylurea, it is best to avoid other similar medications and treat with an unrelated, nonsulfonylurea medication [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MEGLITINIDES</span></p><p class="headingAnchor" id="H4146829027"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Meglitinides are structurally different than sulfonylureas and exert their effects via different pancreatic beta cell receptors, but they act similarly by regulating adenosine triphosphate (ATP)-sensitive potassium channels (K-ATP channels) in pancreatic beta cells, thereby increasing insulin secretion [<a href="#rid49">49</a>]. Meglitinides have a rapid onset and short duration of action [<a href="#rid50">50</a>]. They are administered with meals to reduce postprandial hyperglycemia.</p><p class="headingAnchor" id="H3231243753"><span class="h2">Clinical use of meglitinides</span></p><p class="headingAnchor" id="H3683679294"><span class="h3">Choice of meglitinide and indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">Repaglinide</a> and <a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">nateglinide</a> are short-acting glucose-lowering drugs for therapy of patients with type 2 diabetes. The clinical efficacy of meglitinide monotherapy is similar to that of the sulfonylureas [<a href="#rid50">50-53</a>]. Meglitinides are dosed before each meal, which may limit adherence in some but can be useful in people with unpredictable mealtimes (eg, the medication is not taken if the patient is not eating).</p><p>We generally prefer <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> because of slightly superior glycemic efficacy [<a href="#rid54">54,55</a>]. A meta-analysis of 15 trials to assess the efficacy of meglitinides compared with placebo, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, or in combination with insulin reported that both meglitinides reduced A1C values, with a greater reduction in A1C occurring in those receiving repaglinide compared with <a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">nateglinide</a> (0.1 to 2.1 versus 0.2 to 0.6 percentage-point reduction, respectively) [<a href="#rid56">56</a>]. Repaglinide had similar efficacy in reducing A1C values as metformin, whereas nateglinide was similar or slightly less effective.</p><p><a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">Repaglinide</a> may be useful in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>As initial monotherapy for patients who are intolerant of or have contraindications to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or sulfonylureas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Meglitinides are pharmacologically distinct from sulfonylureas and may be used in patients who have an allergy to sulfonylurea medications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">Repaglinide</a> is particularly useful in patients with chronic kidney disease who cannot or prefer not to take other glucose-lowering medications. Repaglinide is short acting and is principally metabolized by the liver, with less than 10 percent renally excreted. Thus, it can be used safely in patients with nondialysis chronic kidney disease (eg, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>). (See <a class="local">'Dosing and monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Patients not on dialysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As add-on therapy for patients who do not reach glycemic goals with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, particularly if there are contraindications to sulfonylureas or patient preference limits the use of insulin or other agents. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have highly variable diets (eg, inconsistent timing, size, and/or carbohydrate content of meals) or substantial postprandial hyperglycemia with large meals, but do not need additional medication the rest of the time, <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> may be taken at those large or carbohydrate-rich meals only.</p><p></p><p class="headingAnchor" id="H2039238890"><span class="h3">Precautions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">Nateglinide</a> is hepatically metabolized, with renal excretion of active metabolites. It should be used with caution, if at all, in patients with chronic liver or severe kidney disease (eGFR &lt;15 mL/min/1.73 m<sup>2</sup>).</p><p><a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">Repaglinide</a> is metabolized in the liver by CYP2C8, 3A4, and UDP-glucuronosyltransferases (UGT). Strong inhibitors of CYP2C8 (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>) can decrease repaglinide clearance, causing hypoglycemia [<a href="#rid57">57,58</a>]. In addition, the coadministration of <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">gemfibrozil</a> prolongs the plasma concentration of repaglinide, and therefore, they should not be used concomitantly.</p><p class="headingAnchor" id="H9731240"><span class="h3">Dosing and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repaglinide</strong> – The recommended starting dose of <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> is 0.5 mg before each meal for patients with A1C &lt;8 percent. For patients previously treated with oral hypoglycemic drugs and/or whose A1C is ≥8 percent, the starting dose is 1 or 2 mg prior to each meal. </p><p></p><p class="bulletIndent1">The dose may be adjusted at intervals of ≥1 week based on blood glucose monitoring results. The maximum dose of <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> is noted to be up to 4 mg before each meal in the labeling. However, doses higher than 1 or 2 mg prior to each meal are infrequently used. A dose of 1 mg before each meal (3 mg/day) provides most of the glucose-lowering effect [<a href="#rid59">59</a>]. The dose should be skipped if the patient is not eating.</p><p></p><p class="bulletIndent1">Blood glucose monitoring (typically before meals and bedtime over the course of the week, checking all time points but not four times every day) can be performed initially to document efficacy, using blood glucose before the subsequent meal to guide titration of the pre-meal dose. For evaluation of long-term glycemic management, A1C should be measured every three to six months. Routine glucose monitoring may be stopped once the safety and effectiveness of the regimen have been established. (See  <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'Non-insulin treated'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">Repaglinide</a> is principally metabolized by the liver, with less than 10 percent renally excreted. Dose adjustments with this agent do not appear to be necessary in patients with mild to moderate kidney impairment (eGFR ≥40 mL/min/1.73 m<sup>2</sup>). For patients with eGFR between 20 and 40 mL/min/1.73 m<sup>2</sup>, repaglinide 0.5 mg should be initiated before the largest meal and then advanced to 0.5 mg prior to other meals, based upon glucose levels [<a href="#rid60">60</a>]. Repaglinide has not been studied in patients with an eGFR of &lt;20 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nateglinide</strong> – The recommended dose of <a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">nateglinide</a> is 120 mg taken immediately before each meal [<a href="#rid55">55,61</a>]. For people who are near glycemic goals, the initial dose is 60 mg before each meal. If glucose levels are still above target after one to four weeks, the dose may be increased to 120 mg before each meal.</p><p></p><p class="bulletIndent1">No dose adjustments are recommended in patients with mild to severe kidney impairment, but as with all medications that increase endogenous insulin release, they should be titrated slowly based on effect on blood glucose levels.</p><p></p><p class="headingAnchor" id="H1101839652"><span class="h2">Cardiovascular effects</span><span class="headingEndMark"> — </span>There are no long-term studies of meglitinides to assess cardiovascular outcomes or mortality in patients with type 2 diabetes. Whether meglitinides are associated with poorer outcomes in patients who have had a myocardial infarction is not known. However, since their mode of action is so similar to sulfonylureas, the same concern exists. In a retrospective cohort study of patients with type 2 diabetes taking <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a>, <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>, or <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> prior to a hospitalization for coronary heart disease, there was no difference in adverse cardiovascular outcomes at 30 days among the three drugs [<a href="#rid62">62</a>]. Of note, comparisons with other oral or injectable diabetes medications were not performed in this study. (See <a class="local">'Cardiovascular effects'</a> above.)</p><p><a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">Nateglinide</a> has been evaluated for the prevention of diabetes and cardiovascular disease (CVD) in patients with impaired glucose tolerance and one or more risk factors for CVD [<a href="#rid63">63</a>]. It was not effective in the prevention of diabetes or CVD. (See  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Meglitinides have a similar risk for weight gain as sulfonylureas but possibly less risk of hypoglycemia [<a href="#rid64">64,65</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 15 trials comparing the efficacy of meglitinides with placebo, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, or in combination with insulin, symptomatic hypoglycemia (three trials) was reported in 17 to 44 percent of patients [<a href="#rid56">56</a>]. Four trials reported no severe hypoglycemic episodes. Compared with placebo, mean difference in weight ranged from 0 to 2.3 kg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 22 trials comparing <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> plus <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> with metformin alone, the number of hypoglycemic events (nine trials) was similar in the two groups (320 versus 304 with metformin alone, risk ratio [RR] 1.21, 95% CI 0.72-2.04) [<a href="#rid66">66</a>].</p><p></p><p class="headingAnchor" id="H1458529914"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfonylureas</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanism of action</strong> – Sulfonylureas bind to the sulfonylurea receptor on the adenosine triphosphate (ATP)-sensitive potassium channel (K-ATP channel) of the pancreatic beta cells, leading to inhibition of the channels with subsequent alteration of the resting potential of the cell, calcium influx, and stimulation of insulin secretion. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical use</strong> – Sulfonylureas usually lower glycated hemoglobin (A1C) by 1 to 2 percent.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Initial therapy</strong> – A short-acting sulfonylurea (or one with relatively lower risk for hypoglycemia) is a reasonable option for initial therapy (along with lifestyle intervention) in patients without established cardiovascular disease (CVD) who have contraindications to or intolerance of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, particularly if cost is a concern. (See <a class="local">'Initial therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Contraindications to or intolerance of metformin'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Combination therapy</strong> – Sulfonylureas are most often used in combination with other oral hypoglycemic drugs in patients with persistent hyperglycemia after lifestyle intervention and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. They are generally not used in combination with insulin. (See <a class="local">'Combination therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Choice of sulfonylurea</strong> – When a decision has been made to treat with a sulfonylurea, we suggest a shorter-duration sulfonylurea or one with relatively lower risk for hypoglycemia, such as <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8785" href="/z/d/drug information/8785.html" rel="external">gliclazide</a> (not available in the United States), or <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">Glyburide</a> and other long-acting sulfonylureas have a higher incidence of hypoglycemia. (See <a class="local">'Choice of sulfonylurea'</a> above and <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Side effects</strong> – The most common side effects of sulfonylureas are weight gain and hypoglycemia. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meglitinides</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanism of action </strong>– Meglitinides are structurally different from sulfonylureas and exert their effects via different pancreatic beta cell receptors, but they act similarly by regulating K-ATP channels in pancreatic beta cells, thereby increasing insulin secretion. The clinical efficacy of meglitinide monotherapy is similar to that of the sulfonylureas. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical use</strong> – Meglitinides are most commonly used as add-on therapy for patients who do not reach glycemic goals with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, particularly if there are contraindications to sulfonylureas or patient preference limits the use of insulin or other agents. Meglitinides are pharmacologically distinct from sulfonylureas and may be used as initial therapy in patients who have an allergy to sulfonylurea medications. For patients who have highly variable diets (eg, inconsistent timing, size, and/or carbohydrate content of meals) or substantial postprandial hyperglycemia with large meals, but do not need additional medication the rest of the time, <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> may be taken at those large or carbohydrate-rich meals only. (See <a class="local">'Clinical use of meglitinides'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of meglitinide</strong> – When a decision has been made to treat with a meglitinide, we suggest <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Repaglinide has slightly superior glycemic efficacy compared with <a class="drug drug_general" data-topicid="9927" href="/z/d/drug information/9927.html" rel="external">nateglinide</a>. Repaglinide is principally metabolized by the liver, with less than 10 percent renally excreted. Thus, it can be used safely in patients with chronic kidney disease. Nateglinide is hepatically metabolized, with renal excretion of active metabolites. It should be used with caution, if at all, in patients with chronic liver or advanced kidney disease. (See <a class="local">'Choice of meglitinide and indications'</a> above and  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Patients not on dialysis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Side effects</strong> – Meglitinides have a similar risk for weight gain as sulfonylureas but possibly less risk of hypoglycemia. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H1142461749"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268:423.</a></li><li><a class="nounderline abstract_t">Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157:836.</a></li><li><a class="nounderline abstract_t">Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838.</a></li><li><a class="nounderline abstract_t">Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.</a></li><li><a class="nounderline abstract_t">Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.</a></li><li><a class="nounderline abstract_t">Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56:973.</a></li><li><a class="nounderline abstract_t">Davidson MB. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents. West J Med 1992; 157:199.</a></li><li><a class="nounderline abstract_t">Shepherd M, Shields B, Ellard S, et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26:437.</a></li><li><a class="nounderline abstract_t">Hermann LS, Scherstén B, Bitzén PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.</a></li><li><a class="nounderline abstract_t">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:740.</a></li><li><a class="nounderline abstract_t">GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022; 387:1063.</a></li><li><a class="nounderline abstract_t">Douros A, Dell'Aniello S, Yu OHY, Suissa S. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study. Diabetes Obes Metab 2020; 22:254.</a></li><li><a class="nounderline abstract_t">Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract 2015; 110:75.</a></li><li><a class="nounderline abstract_t">Douros A, Yin H, Yu OHY, et al. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care 2017; 40:1506.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019; 322:1155.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321:69.</a></li><li><a class="nounderline abstract_t">Wexler DJ. Sulfonylureas and Cardiovascular Safety: The Final Verdict? JAMA 2019; 322:1147.</a></li><li><a class="nounderline abstract_t">Rydberg T, Jönsson A, Røder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17:1026.</a></li><li><a class="nounderline abstract_t">Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118:169.</a></li><li><a class="nounderline abstract_t">Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15:938.</a></li><li><a class="nounderline abstract_t">Varvaki Rados D, Catani Pinto L, Reck Remonti L, et al. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. PLoS Med 2016; 13:e1001992.</a></li><li><a class="nounderline abstract_t">GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022; 387:1075.</a></li><li><a class="nounderline abstract_t">Wang H, Cordiner RLM, Huang Y, et al. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care 2023; 46:967.</a></li><li><a class="nounderline abstract_t">Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care 2017; 40:706.</a></li><li><a class="nounderline abstract_t">Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36:1304.</a></li><li><a class="nounderline abstract_t">Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174:169.</a></li><li><a class="nounderline abstract_t">Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157:601.</a></li><li><a class="nounderline abstract_t">Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32:1900.</a></li><li><a class="nounderline abstract_t">Roumie CL, Chipman J, Min JY, et al. Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. JAMA 2019; 322:1167.</a></li><li><a class="nounderline abstract_t">A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25:1129.</a></li><li><a class="nounderline abstract_t">Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201.</a></li><li><a class="nounderline abstract_t">Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33:119.</a></li><li><a class="nounderline abstract_t">Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314:1512.</a></li><li><a class="nounderline abstract_t">Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95:4993.</a></li><li><a class="nounderline abstract_t">Leonard CE, Hennessy S, Han X, et al. Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab 2017; 28:561.</a></li><li><a class="nounderline abstract_t">Schopman JE, Simon AC, Hoefnagel SJ, et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014; 30:11.</a></li><li><a class="nounderline abstract_t">Yu O, Azoulay L, Yin H, et al. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Am J Med 2018; 131:317.e11.</a></li><li><a class="nounderline abstract_t">Tessier D, Dawson K, Tétrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11:974.</a></li><li><a class="nounderline abstract_t">Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17:467.</a></li><li><a class="nounderline abstract_t">Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30:389.</a></li><li><a class="nounderline abstract_t">Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44:751.</a></li><li><a class="nounderline abstract_t">Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157:1681.</a></li><li><a class="nounderline abstract_t">Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34:535.</a></li><li><a class="nounderline abstract_t">Colagiuri S, Matthews D, Leiter LA, et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract 2018; 143:1.</a></li><li><a class="nounderline abstract_t">Seligman HK, Jacobs EA, Lopez A, et al. Food insecurity and hypoglycemia among safety net patients with diabetes. Arch Intern Med 2011; 171:1204.</a></li><li><a class="nounderline abstract_t">Bressler P, DeFronzo RA. Drugs and diabetes. Diabetes Reviews 1994; 2:53.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA 2016; 316:313.</a></li><li><a class="nounderline abstract_t">Chichmanian RM, Papasseudi G, Hieronimus S, et al. [Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?]. Therapie 1991; 46:163.</a></li><li><a class="nounderline abstract_t">Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345.</a></li><li><a class="nounderline abstract_t">Repaglinide for type 2 diabetes mellitus. Med Lett Drugs Ther 1998; 40:55.</a></li><li><a class="nounderline abstract_t">Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22:463.</a></li><li><a class="nounderline abstract_t">Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22:119.</a></li><li><a class="nounderline abstract_t">Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24:983.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27:1265.</a></li><li><a class="nounderline abstract_t">Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26:2063.</a></li><li><a class="nounderline abstract_t">Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; :CD004654.</a></li><li><a class="nounderline abstract_t">Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 2014; 96:498.</a></li><li><a class="nounderline abstract_t">Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev 2016; 68:168.</a></li><li><a class="nounderline abstract_t">DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281.</a></li><li><a class="nounderline abstract_t">Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886.</a></li><li><a class="nounderline abstract_t">Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001; 24:1221.</a></li><li><a class="nounderline abstract_t">Huang Y, Abdelmoneim AS, Light P, et al. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications 2015; 29:196.</a></li><li><a class="nounderline abstract_t">NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1463.</a></li><li><a class="nounderline abstract_t">Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, et al. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci 2013; 9:936.</a></li><li><a class="nounderline abstract_t">Meneilly GS. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. Diabetes Technol Ther 2011; 13:63.</a></li><li><a class="nounderline abstract_t">Yin J, Deng H, Qin S, et al. Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2014; 105:e10.</a></li></ol></div><div id="topicVersionRevision">Topic 1786 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7716547" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129543" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115830" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885549" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885550" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23494446" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1441492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19388975" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821128" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27088241" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31596043" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361859" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864502" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418475" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536110" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sulfonylureas and Cardiovascular Safety: The Final Verdict?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7988301" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417634" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : What is the benefit of increasing the sulfonylurea dose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594109" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27071029" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129997" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36944118" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28428321" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23230096" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415461" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471135" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536102" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/992232" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693990" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935017" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169397" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20702526" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28545784" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030920" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032229" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7895463" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Glibenclamide vs gliclazide in type 2 diabetes of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757083" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259518" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675920" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Individual sulfonylureas and serious hypoglycemia in older people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250229" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305887" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29802958" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747017" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Food insecurity and hypoglycemia among safety net patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drugs and diabetes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434443" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1828914" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9519738" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9618664" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Repaglinide for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10097930" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333912" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11375357" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161773" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832314" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443551" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Meglitinide analogues for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24971633" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721703" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454950" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pharmacologic therapy for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423506" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534984" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20228402" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of nateglinide on the incidence of diabetes and cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24273582" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175273" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25005849" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
